Last reviewed · How we verify
NCT05971082: FLD_FU_HUS
Risk Factors for Advanced Fibrosis Among FLD Patients
trial testing Follow-up in NAFLD in 1,000 participants. Status unknown.
31 December 2025
Quick facts
| Lead sponsor | Helsinki University Central Hospital |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 1,000 |
| Start date | 24 August 2023 |
| Primary completion | 31 December 2025 |
| Estimated completion | 31 December 2025 |
| Sites | 1 location across Finland |
Drugs / interventions tested
- Follow-up
Conditions studied
- NAFLD — all drugs for NAFLD →
- Liver Cirrhosis — all drugs for Liver Cirrhosis →
- Diabetes Mellitus, Type 2 — all drugs for Diabetes Mellitus, Type 2 →
Sponsor
Helsinki University Central Hospital
Who can join
Adults 25 to 70, any sex, with NAFLD or Liver Cirrhosis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The investigators investigate the heterogeneity fatty liver disease (FLD) as well as risk factors associated with progression of the liver diseases or development of cardiovascular complication. The overarching aim is to develop a AI-based prediction model that could be integrated into the electronic medical record system. To identify large numbers of unselected individuals with FLD, the investigators developed a phrase recognition algorithm, which identifies FLD using radiology reports. Within the data lake of Helsinki University Hospital, they identified a large number of individuals with or without FLD. The investigators will now randomly invite 1000-1500 individuals with FLD to a follow-up study including investigation of metabolism and progression of liver disease (elastography, blood tests) as well as gathering life-style information. Register data on previous diagnoses and medication will be used to evaluate cardiovascular disease.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05971082
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Follow-up
Trials testing the same drug.
- NCT06743282 — Senyo Health With Substance Use Disorder (SUD) in Primary Care · NA · enrolling by invitation
- NCT07007377 — Can the Ergometric Test in Flu-like Syndrome Help in the Outcome Analysis of Unvaccinated Patients · recruiting
- NCT06866483 — Validation and Scaling of Screening Program for Undiagnosed Myasthenia Gravis-Social Media Campaign Paired With a Self-m · recruiting
- NCT06651203 — Evaluation of the KIR3DL2 Marker in Flow Cytometry for Sézary Syndrome Diagnosis, Therapeutic Response and Residual Dise · not yet recruiting
- NCT06381284 — Expediting Myasthenia Gravis (MG) Diagnostic Evaluation: A Novel, Proof-of-Concept for Undiagnosed, Symptomatic Patients · completed
Other recruiting trials for NAFLD
Currently open trials in the same condition.
- NCT07518784 — Accurate Point of Care Liver Disease Diagnostics (Phase 2) · recruiting
- NCT06661655 — Evaluation of a New Ultrasound System for the Non-invasive Assessment of Liver Steatosis in MASLD/MASH Patients · NA · recruiting
- NCT07093346 — The Impact of Pectin Supplementation on Systematic Inflammation Pathway, Gut Microbiome, and Metabolic Health in Patient · NA · recruiting
- NCT06879236 — Secondary and Tertiary Digital Prevention of Non-alcoholic and Dysmetabolic Liver Disease · recruiting
- NCT06888310 — Optimizing Noninvasive assessMent Of DysmEtabolic Compensated Advanced Liver Disease · NA · recruiting
Other Helsinki University Central Hospital trials
Trials by the same sponsor.
- NCT07423637 — The Impact of Early Automated Insulin Delivery (AID) Therapy on Diabetes Control and Comorbidities, and Cost-effectivene · NA · not yet recruiting
- NCT07462559 — KF2025#1 Trial: Ketamine, Cannabidiol and Cobicistat Interaction Study · Phase 1 · not yet recruiting
- NCT07458984 — FMT Capsules for rCDI · Phase 3 · not yet recruiting
- NCT07001423 — ChOlecystectomy aFter successFul Endoscopic Common Bile Duct Stone Extraction in Elderly · NA · recruiting
- NCT07155629 — Neoadjuvant Treatment vs Upfront Surgery for Left-Sided Pancreatic Cancer · Phase 3 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05971082 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Helsinki University Central Hospital
- Last refreshed: 17 October 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05971082.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing